Piper Sandler upgraded ImmunityBio (IBRX) to Overweight from Neutral with a price target of $5, up from $4.25.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Short Report: Bears not fearing rebound in Rocket, Avis Budget shares
- ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum
- ImmunityBio’s Promising Growth and Strategic Expansion Justify Buy Rating Despite Regulatory Setback
- ImmunityBio reports Q1 EPS (15c), consensus (14c)
- Biotech Alert: Searches spiking for these stocks today